

Barton F Haynes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758753/publications.pdf>

Version: 2024-02-01

256
papers

28,963
citations

7568

77
h-index

6471

157
g-index

277
all docs

277
docs citations

277
times ranked

20259
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annual Review of Medicine, 2022, 73, 1-16.	12.2	91
2	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. Science Translational Medicine, 2022, 14, eabj7125.	12.4	93
3	Development of mRNA manufacturing for vaccines and therapeutics: mRNA platform requirements and development of a scalable production process to support early phase clinical trials. Translational Research, 2022, 242, 38-55.	5.0	41
4	Structural diversity of the SARS-CoV-2 Omicron spike. Molecular Cell, 2022, 82, 2050-2068.e6.	9.7	125
5	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	4.4	14
6	mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Cell Reports, 2022, 38, 110514.	6.4	23
7	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	11.0	308
8	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science, 2021, 371, .	12.6	49
9	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Reports, 2021, 34, 108630.	6.4	263
10	HIV mRNA Vaccinesâ€™ Progress and Future Paths. Vaccines, 2021, 9, 134.	4.4	45
11	Vaccine Innovations â€™ Past and Future. New England Journal of Medicine, 2021, 384, 393-396.	27.0	23
12	A New Vaccine to Battle Covid-19. New England Journal of Medicine, 2021, 384, 470-471.	27.0	50
13	Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors. Cell Reports Medicine, 2021, 2, 100207.	6.5	26
14	Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates. Npj Vaccines, 2021, 6, 50.	6.0	46
15	SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host and Microbe, 2021, 29, 529-539.e3.	11.0	324
16	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature, 2021, 594, 553-559.	27.8	199
17	Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. Cell Reports, 2021, 35, 109179.	6.4	63
18	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. Cell, 2021, 184, 2955-2972.e25.	28.9	57

#	ARTICLE	IF	CITATIONS
19	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention, and Cure. <i>Journal of Virology</i> , 2021, 95, .	3.4	21
20	Cross-reactive coronavirus antibodies with diverse epitope specificities and Fc effector functions. <i>Cell Reports Medicine</i> , 2021, 2, 100313.	6.5	56
21	Structural and genetic convergence of HIV-1 neutralizing antibodies in vaccinated non-human primates. <i>PLoS Pathogens</i> , 2021, 17, e1009624.	4.7	2
22	SARS-CoV-2 and HIV-1 “a tale of two vaccines. <i>Nature Reviews Immunology</i> , 2021, 21, 543-544.	22.7	7
23	HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth. <i>Scientific Reports</i> , 2021, 11, 14494.	3.3	6
24	Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations. <i>Cell Reports</i> , 2021, 36, 109561.	6.4	9
25	InÂvitro and inÂvivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. <i>Cell</i> , 2021, 184, 4203-4219.e32.	28.9	228
26	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	12.6	144
27	The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination. <i>Nature Immunology</i> , 2021, 22, 1294-1305.	14.5	20
28	Cold sensitivity of the SARS-CoV-2 spike ectodomain. <i>Nature Structural and Molecular Biology</i> , 2021, 28, 128-131.	8.2	65
29	Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. <i>Cell Reports</i> , 2021, 37, 109922.	6.4	5
30	Selection of HIV Envelope strains for standardized assessments of vaccine-elicited antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies. <i>Journal of Virology</i> , 2021, , JVI0164321.	3.4	7
31	Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination. <i>Current Opinion in Virology</i> , 2021, 51, 172-178.	5.4	13
32	Strategies for induction of HIVâ€1 envelopeâ€reactive broadly neutralizing antibodies. <i>Journal of the International AIDS Society</i> , 2021, 24, e25831.	3.0	19
33	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	6
34	Prospects for a safe COVID-19 vaccine. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	204
35	Immunogenicity, safety, and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs. <i>Npj Vaccines</i> , 2020, 5, 107.	6.0	11
36	Recognition Patterns of the C1/C2 Epitopes Involved in Fc-Mediated Response in HIV-1 Natural Infection and the RV114 Vaccine Trial. <i>MBio</i> , 2020, 11, .	4.1	6

#	ARTICLE	IF	CITATIONS
37	A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice. <i>Immunity</i> , 2020, 53, 724-732.e7.	14.3	267
38	Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor. <i>Journal of Virology</i> , 2020, 94, .	3.4	5
39	How Does HIV Env Structure Informs Vaccine Design?. <i>Microscopy and Microanalysis</i> , 2020, 26, 574-575.	0.4	0
40	Therapeutic vaccination with IDLV-SIV-Gag results in durable viremia control in chronically SHIV-infected macaques. <i>Npj Vaccines</i> , 2020, 5, 36.	6.0	12
41	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. <i>Cell Reports</i> , 2020, 31, 107624.	6.4	43
42	Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. <i>MBio</i> , 2020, 11, .	4.1	25
43	Pandemic Preparedness: Developing Vaccines and Therapeutic Antibodies For COVID-19. <i>Cell</i> , 2020, 181, 1458-1463.	28.9	92
44	Conditional antibody expression to avoid central B cell deletion in humanized HIV-1 vaccine mouse models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7929-7940.	7.1	10
45	Subordinate Effect of -21M HLA-B Dimorphism on NK Cell Repertoire Diversity and Function in HIV-1 Infected Individuals of African Origin. <i>Frontiers in Immunology</i> , 2020, 11, 156.	4.8	6
46	Induction of Neutralizing Responses against Autologous Virus in Maternal HIV Vaccine Trials. <i>MSphere</i> , 2020, 5, .	2.9	2
47	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	12.8	27
48	Neonatal Rhesus Macaques Have Distinct Immune Cell Transcriptional Profiles following HIV Envelope Immunization. <i>Cell Reports</i> , 2020, 30, 1553-1569.e6.	6.4	21
49	Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements. <i>Nature Communications</i> , 2020, 11, 520.	12.8	42
50	Aberrant B cell repertoire selection associated with HIV neutralizing antibody breadth. <i>Nature Immunology</i> , 2020, 21, 199-209.	14.5	68
51	HIV vaccine delayed boosting increases Env variable region 2â€™specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	5.0	18
52	Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies. <i>Journal of Clinical Investigation</i> , 2020, 130, 5157-5170.	8.2	22
53	-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures. <i>ImmunoHorizons</i> , 2020, 4, 713-728.	1.8	0
54	HLA class II-Restricted CD8+ T cells in HIV-1 Virus Controllers. <i>Scientific Reports</i> , 2019, 9, 10165.	3.3	7

#	ARTICLE	IF	CITATIONS
55	Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 14, 148-160.	4.1	4
56	Difficult-to-neutralize global HIV-1 isolates are neutralized by antibodies targeting open envelope conformations. <i>Nature Communications</i> , 2019, 10, 2898.	12.8	35
57	Multiple roles for HIV broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	144
58	Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2019, 15, e1008026.	4.7	56
59	Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates. <i>PLoS Biology</i> , 2019, 17, e3000328.	5.6	33
60	The Chimpanzee SIV Envelope Trimer: Structure and Deployment as an HIV Vaccine Template. <i>Cell Reports</i> , 2019, 27, 2426-2441.e6.	6.4	35
61	Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. <i>PLoS ONE</i> , 2019, 14, e0215163.	2.5	41
62	Longitudinal Analysis Reveals Early Development of Three MPER-Directed Neutralizing Antibody Lineages from an HIV-1-Infected Individual. <i>Immunity</i> , 2019, 50, 677-691.e13.	14.3	77
63	Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 15, 36-47.	5.1	79
64	Selection of immunoglobulin elbow region mutations impacts interdomain conformational flexibility in HIV-1 broadly neutralizing antibodies. <i>Nature Communications</i> , 2019, 10, 654.	12.8	34
65	Contribution of proteasome-catalyzed peptide cis-splicing to viral targeting by CD8 ⁺ T cells in HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24748-24759.	7.1	48
66	Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. <i>Journal of Immunology</i> , 2019, 203, 3268-3281.	0.8	12
67	Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans. <i>PLoS Pathogens</i> , 2019, 15, e1008165.	4.7	5
68	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. <i>Science</i> , 2019, 366, .	12.6	118
69	HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design. <i>Cell Host and Microbe</i> , 2019, 25, 59-72.e8.	11.0	124
70	Self-tolerance curtails the B cell repertoire to microbial epitopes. <i>JCI Insight</i> , 2019, 4, .	5.0	32
71	Vaccine induction of antibodies and tissue-resident CD8 ⁺ T cells enhances protection against mucosal SHIV-infection in young macaques. <i>JCI Insight</i> , 2019, 4, .	5.0	50
72	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46

#	ARTICLE	IF	CITATIONS
73	Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
74	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
75	HIV envelope V3 region mimic embodies key features of a broadly neutralizing antibody lineage epitope. <i>Nature Communications</i> , 2018, 9, 1111.	12.8	30
76	What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination?. <i>Cold Spring Harbor Perspectives in Biology</i> , 2018, 10, a029397.	5.5	10
77	Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. <i>Journal of Virology</i> , 2018, 92, .	3.4	24
78	IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells. <i>Communications Biology</i> , 2018, 1, 134.	4.4	26
79	HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies. <i>PLoS Pathogens</i> , 2018, 14, e1007431.	4.7	36
80	Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier. <i>Immunity</i> , 2018, 49, 1162-1174.e8.	14.3	61
81	RAB11FIP5 Expression and Altered Natural Killer Cell Function Are Associated with Induction of HIV Broadly Neutralizing Antibody Responses. <i>Cell</i> , 2018, 175, 387-399.e17.	28.9	78
82	Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. <i>Cell Reports</i> , 2018, 25, 107-117.e3.	6.4	79
83	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. <i>Cell Reports</i> , 2018, 25, 893-908.e7.	6.4	91
84	Route of immunization defines multiple mechanisms of vaccine-mediated protection against SIV. <i>Nature Medicine</i> , 2018, 24, 1590-1598.	30.7	129
85	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. <i>Nature Communications</i> , 2018, 9, 1928.	12.8	83
86	Glycoengineering HIV-1 Env creates "supercharged" and "hybrid" glycans to increase neutralizing antibody potency, breadth and saturation. <i>PLoS Pathogens</i> , 2018, 14, e1007024.	4.7	22
87	Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection. <i>Frontiers in Microbiology</i> , 2018, 9, 1326.	3.5	13
88	Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. <i>Journal of Experimental Medicine</i> , 2018, 215, 1571-1588.	8.5	366
89	Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development. <i>Cell Host and Microbe</i> , 2018, 23, 759-765.e6.	11.0	98
90	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. <i>Nature Communications</i> , 2018, 9, 2363.	12.8	46

#	ARTICLE	IF	CITATIONS
91	Systemic administration of an HIV-1 broadly neutralizing dimeric IgA yields mucosal secretory IgA and virus neutralization. <i>Mucosal Immunology</i> , 2017, 10, 228-237.	6.0	34
92	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E590-E599.	7.1	137
93	The quest for an antibody-based HIV vaccine. <i>Immunological Reviews</i> , 2017, 275, 5-10.	6.0	91
94	Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. <i>Nature</i> , 2017, 543, 248-251.	27.8	699
95	Antibody-virus evolution in HIV infection: paths for HIV vaccine development. <i>Immunological Reviews</i> , 2017, 275, 145-160.	6.0	160
96	Host controls of HIV broadly neutralizing antibody development. <i>Immunological Reviews</i> , 2017, 275, 79-88.	6.0	65
97	Immunodominance of Antibody Recognition of the HIV Envelope V2 Region in Ig-Humanized Mice. <i>Journal of Immunology</i> , 2017, 198, 1047-1055.	0.8	7
98	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. <i>Journal of Virology</i> , 2017, 91, .	3.4	52
99	Glycosylation Benchmark Profile for HIV-1 Envelope Glycoprotein Production Based on Eleven Env Trimers. <i>Journal of Virology</i> , 2017, 91, .	3.4	73
100	BCR and Endosomal TLR Signals Synergize to Increase AID Expression and Establish Central B Cell Tolerance. <i>Cell Reports</i> , 2017, 18, 1627-1635.	6.4	49
101	Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. <i>Science Immunology</i> , 2017, 2, .	11.9	119
102	Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates. <i>Cell Reports</i> , 2017, 18, 2175-2188.	6.4	69
103	Quantification of the Impact of the HIV-1-Glycan Shield on Antibody Elicitation. <i>Cell Reports</i> , 2017, 19, 719-732.	6.4	160
104	Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. <i>Nature Communications</i> , 2017, 8, 15711.	12.8	137
105	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	212
106	Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	81
107	Developing an HIV vaccine. <i>Science</i> , 2017, 355, 1129-1130.	12.6	89
108	HIV-1 Consensus Envelope-Induced Broadly Binding Antibodies. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 859-868.	1.1	18

#	ARTICLE	IF	CITATIONS
109	HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine. <i>Journal of Virology</i> , 2017, 91, .	3.4	23
110	Development of a recombinant yellow fever vector expressing a HIV clade C founder envelope gp120. <i>Journal of Virological Methods</i> , 2017, 249, 85-93.	2.1	2
111	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017, 91, .	3.4	19
112	Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 8614-8619.	7.1	42
113	HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques. <i>Journal of Virology</i> , 2017, 91, .	3.4	20
114	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 428-431.	1.1	26
115	Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. <i>Journal of Virology</i> , 2017, 91, .	3.4	29
116	Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models. <i>Cell Reports</i> , 2017, 21, 3681-3690.	6.4	97
117	Structure and Diversity of the Rhesus Macaque Immunoglobulin Loci through Multiple De Novo Genome Assemblies. <i>Frontiers in Immunology</i> , 2017, 8, 1407.	4.8	66
118	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	2.5	12
119	Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. <i>Nature Communications</i> , 2017, 8, 1732.	12.8	76
120	Computational analysis of antibody dynamics identifies recent HIV-1 infection. <i>JCI Insight</i> , 2017, 2, .	5.0	11
121	Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques. <i>Molecular Therapy</i> , 2016, 24, 2021-2032.	8.2	41
122	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
123	HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. <i>Immunogenetics</i> , 2016, 68, 145-155.	2.4	18
124	Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design. <i>Journal of Virology</i> , 2016, 90, 5899-5914.	3.4	62
125	A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. <i>Cell Reports</i> , 2016, 15, 1505-1513.	6.4	43
126	Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. <i>Cell</i> , 2016, 166, 1471-1484.e18.	28.9	198

#	ARTICLE	IF	CITATIONS
127	Novel Monoclonal Antibodies for Studies of Human and Rhesus Macaque Secretory Component and Human J-Chain. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2016, 35, 217-226.	1.6	9
128	HIV-1 Envelope Mimicry of Host Enzyme Kynureninase Does Not Disrupt Tryptophan Metabolism. <i>Journal of Immunology</i> , 2016, 197, 4663-4673.	0.8	6
129	Latency reversal and viral clearance to cure HIV-1. <i>Science</i> , 2016, 353, aaf6517.	12.6	194
130	Initiation of immune tolerance—controlled HIV gp41 neutralizing B cell lineages. <i>Science Translational Medicine</i> , 2016, 8, 336ra62.	12.4	86
131	Immune perturbations in HIV-1—infected individuals who make broadly neutralizing antibodies. <i>Science Immunology</i> , 2016, 1, aag0851.	11.9	120
132	Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. <i>Nature Medicine</i> , 2016, 22, 1465-1469.	30.7	104
133	Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity. <i>EBioMedicine</i> , 2016, 12, 196-207.	6.1	34
134	Envelope residue 375 substitutions in simian—human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3413-22.	7.1	170
135	Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds. <i>Journal of Virology</i> , 2016, 90, 5031-5046.	3.4	38
136	HIV-Host Interactions: Implications for Vaccine Design. <i>Cell Host and Microbe</i> , 2016, 19, 292-303.	11.0	143
137	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. <i>Cell</i> , 2016, 165, 449-463.	28.9	305
138	Combined HIV-1 Envelope Systemic and Mucosal Immunization of Lactating Rhesus Monkeys Induces a Robust Immunoglobulin A Isotype B Cell Response in Breast Milk. <i>Journal of Virology</i> , 2016, 90, 4951-4965.	3.4	23
139	Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. <i>Nature Structural and Molecular Biology</i> , 2016, 23, 81-90.	8.2	162
140	Structural Constraints of Vaccine-Induced Tier-2 Autologous HIV Neutralizing Antibodies Targeting the Receptor-Binding Site. <i>Cell Reports</i> , 2016, 14, 43-54.	6.4	45
141	New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency. <i>Journal of Virology</i> , 2016, 90, 76-91.	3.4	205
142	Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. <i>PLoS ONE</i> , 2016, 11, e0157391.	2.5	33
143	Developmental Pathway of the MPER-Directed HIV-1-Neutralizing Antibody 10E8. <i>PLoS ONE</i> , 2016, 11, e0157409.	2.5	44
144	Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. <i>Cell Reports</i> , 2015, 13, 2842-2850.	6.4	67

#	ARTICLE	IF	CITATIONS
145	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. <i>Viruses</i> , 2015, 7, 5443-5475.	3.3	26
146	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
147	New approaches to HIV vaccine development. <i>Current Opinion in Immunology</i> , 2015, 35, 39-47.	5.5	77
148	Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. <i>Cell</i> , 2015, 161, 1280-1292.	28.9	305
149	Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission. <i>Journal of Virology</i> , 2015, 89, 7813-7828.	3.4	35
150	Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost. <i>Journal of Virology</i> , 2015, 89, 6462-6480.	3.4	40
151	Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. <i>Science</i> , 2015, 349, aab1253.	12.6	191
152	Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors. <i>Vaccine Journal</i> , 2015, 22, 726-741.	3.1	16
153	Broadly Neutralizing Antibodies and the Development of Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2419.	7.4	15
154	Viral Receptor-Binding Site Antibodies with Diverse Germline Origins. <i>Cell</i> , 2015, 161, 1026-1034.	28.9	151
155	CD4 mimetics sensitize HIV-1-infected cells to ADCC. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2687-94.	7.1	118
156	Designing synthetic vaccines for HIV. <i>Expert Review of Vaccines</i> , 2015, 14, 815-831.	4.4	28
157	Eliminating antibody polyreactivity through addition of N-linked glycosylation. <i>Protein Science</i> , 2015, 24, 1019-1030.	7.6	11
158	Immune correlates of vaccine protection against HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 310rv7.	12.4	179
159	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015, 2, 713-722.	6.1	13
160	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. <i>Cell Host and Microbe</i> , 2015, 18, 354-362.	11.0	66
161	Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. <i>Journal of Infectious Diseases</i> , 2015, 211, 947-955.	4.0	140
162	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. <i>Virology</i> , 2015, 475, 37-45.	2.4	25

#	ARTICLE	IF	CITATIONS
163	Polyreactivity and Autoreactivity among HIV-1 Antibodies. <i>Journal of Virology</i> , 2015, 89, 784-798.	3.4	154
164	Improving <i>Mycobacterium bovis</i> Bacillus Calmette-Guérin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells. <i>PLoS ONE</i> , 2014, 9, e108383.	2.5	24
165	Immune System Regulation in the Induction of Broadly Neutralizing HIV-1 Antibodies. <i>Vaccines</i> , 2014, 2, 1-14.	4.4	25
166	Progress in HIV-1 vaccine development. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 3-10.	2.9	62
167	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	2.0	26
168	Preexisting compensatory amino acids compromise fitness costs of a HIV-1 cell escape mutation. <i>Retrovirology</i> , 2014, 11, 101.	2.0	12
169	Recombinant <i>Mycobacterium bovis</i> Bacillus Calmette-Guérin Vectors Prime for Strong Cellular Responses to Simian Immunodeficiency Virus Gag in Rhesus Macaques. <i>Vaccine Journal</i> , 2014, 21, 1385-1395.	3.1	13
170	HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development. <i>PLoS Pathogens</i> , 2014, 10, e1004073.	4.7	26
171	Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. <i>Frontiers in Immunology</i> , 2014, 5, 170.	4.8	104
172	Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 10275-10280.	7.1	73
173	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	3.4	169
174	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65
175	Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX [®] B/E in RV144 Vaccinees. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A36-A36.	1.1	1
176	IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. <i>PLoS ONE</i> , 2014, 9, e90725.	2.5	37
177	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu056.	0.9	19
178	Gene Deletions in <i>Mycobacterium bovis</i> BCG Stimulate Increased CD8 ⁺ T Cell Responses. <i>Infection and Immunity</i> , 2014, 82, 5317-5326.	2.2	13
179	Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection. <i>Vaccine</i> , 2014, 32, 3995-4000.	3.8	4
180	Host Controls of HIV Neutralizing Antibodies. <i>Science</i> , 2014, 344, 588-589.	12.6	63

#	ARTICLE	IF	CITATIONS
181	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	3.4	248
182	Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies. <i>Cell Host and Microbe</i> , 2014, 16, 304-313.	11.0	137
183	Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements. <i>Cell Host and Microbe</i> , 2014, 16, 105-114.	11.0	246
184	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	3.4	16
185	CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies. <i>Journal of Virology</i> , 2014, 88, 6542-6555.	3.4	55
186	HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria. <i>Cell Host and Microbe</i> , 2014, 16, 215-226.	11.0	105
187	Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies. <i>Cell</i> , 2014, 158, 481-491.	28.9	266
188	Structure and immune recognition of trimeric pre-fusion HIV-1 Env. <i>Nature</i> , 2014, 514, 455-461.	27.8	702
189	Lessons from babies: inducing HIV-1 broadly neutralizing antibodies. <i>Nature Medicine</i> , 2014, 20, 583-585.	30.7	7
190	Redemption of autoreactive B cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 9022-9023.	7.1	11
191	The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved Human Peripheral Blood Mononuclear Cells. <i>Journal of Immunological Methods</i> , 2014, 409, 21-30.	1.4	19
192	Chemical Synthesis of Highly Congested gp120 V1V2 <i>N</i> -Glycopeptide Antigens for Potential HIV-1-Directed Vaccines. <i>Journal of the American Chemical Society</i> , 2013, 135, 13113-13120.	13.7	60
193	Multidonor Analysis Reveals Structural Elements, Genetic Determinants, and Maturation Pathway for HIV-1 Neutralization by VRC01-Class Antibodies. <i>Immunity</i> , 2013, 39, 245-258.	14.3	332
194	HIV-1 neutralizing antibodies: understanding nature's pathways. <i>Immunological Reviews</i> , 2013, 254, 225-244.	6.0	442
195	Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10. <i>Journal of Immunology</i> , 2013, 191, 1260-1275.	0.8	77
196	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. <i>Nature</i> , 2013, 496, 469-476.	27.8	961
197	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	14.3	374
198	Progress in HIV-1 vaccine development. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 1.	3.8	45

#	ARTICLE	IF	CITATIONS
199	Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18214-18219.	7.1	73
200	B-cell lineage immunogen design in vaccine development with HIV-1 as a case study. Nature Biotechnology, 2012, 30, 423-433.	17.5	432
201	Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design. Journal of Virology, 2012, 86, 4688-4692.	3.4	159
202	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. New England Journal of Medicine, 2012, 366, 1275-1286.	27.0	1,699
203	Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. Journal of Virology, 2011, 85, 9998-10009.	3.4	393
204	Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. Journal of Experimental Medicine, 2011, 208, 2237-2249.	8.5	198
205	B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. Trends in Molecular Medicine, 2011, 17, 108-116.	6.7	37
206	Isolation of a Monoclonal Antibody That Targets the Alpha-2 Helix of gp120 and Represents the Initial Autologous Neutralizing-Antibody Response in an HIV-1 Subtype C-Infected Individual. Journal of Virology, 2011, 85, 7719-7729.	3.4	54
207	Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting. PLoS ONE, 2011, 6, e23532.	2.5	137
208	Is developing an HIV-1 vaccine possible?. Current Opinion in HIV and AIDS, 2010, 5, 362-367.	3.8	28
209	HIV-1 autoreactive antibodies: are they good or bad for HIV-1 prevention?. Nature Structural and Molecular Biology, 2010, 17, 543-545.	8.2	18
210	Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 181-186.	7.1	172
211	Genetic Signatures in the Envelope Glycoproteins of HIV-1 that Associate with Broadly Neutralizing Antibodies. PLoS Computational Biology, 2010, 6, e1000955.	3.2	78
212	High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods, 2009, 158, 171-179.	2.1	235
213	Glycosylation Site-Specific Analysis of Clade C HIV-1 Envelope Proteins. Journal of Proteome Research, 2009, 8, 4231-4242.	3.7	87
214	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1273-1289.	8.5	684
215	Comparison of HPLC/ESI-FTICR MS versus MALDI-TOF/TOF MS for glycopeptide analysis of a highly glycosylated HIV envelope glycoprotein. Journal of the American Society for Mass Spectrometry, 2008, 19, 1209-1220.	2.8	69
216	Critical issues in mucosal immunity for HIV-1 vaccine development. Journal of Allergy and Clinical Immunology, 2008, 122, 3-9.	2.9	68

#	ARTICLE	IF	CITATIONS
217	Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia. <i>Journal of Virology</i> , 2008, 82, 12449-12463.	3.4	548
218	HIV-1 Hides an Achilles' Heel in Virion Lipids. <i>Immunity</i> , 2008, 28, 10-12.	14.3	26
219	Glycosylation Site-Specific Analysis of HIV Envelope Proteins (JR-FL and CON-S) Reveals Major Differences in Glycosylation Site Occupancy, Glycoform Profiles, and Antigenic Epitopes' Accessibility. <i>Journal of Proteome Research</i> , 2008, 7, 1660-1674.	3.7	133
220	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 7552-7557.	7.1	1,708
221	High throughput functional analysis of HIV-1 env genes without cloning. <i>Journal of Virological Methods</i> , 2007, 143, 104-111.	2.1	45
222	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. <i>Expert Review of Vaccines</i> , 2006, 5, 347-363.	4.4	90
223	Antibody polyspecificity and neutralization of HIV-1: A hypothesis. <i>Human Antibodies</i> , 2006, 14, 59-67.	1.5	142
224	Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. <i>Virology</i> , 2006, 345, 44-55.	2.4	37
225	Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. <i>Expert Review of Vaccines</i> , 2006, 5, 579-595.	4.4	87
226	Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. <i>Science</i> , 2005, 308, 1906-1908.	12.6	704
227	Antibody polyspecificity and neutralization of HIV-1: a hypothesis. <i>Human Antibodies</i> , 2005, 14, 59-67.	1.5	109
228	Thymopoiesis in HIV-Infected Adults after Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1635-1643.	1.1	45
229	Can the thymus win the battle against drug-resistant HIV?. <i>Nature Medicine</i> , 2001, 7, 661-662.	30.7	1
230	The Human Thymus During Aging. <i>Immunologic Research</i> , 2000, 22, 253-262.	2.9	133
231	HIV Vaccine Development at Duke University Medical Center. <i>Immunologic Research</i> , 2000, 22, 263-270.	2.9	0
232	Cytokines and adhesion molecules in the pathogenesis of vasculitis. <i>Current Rheumatology Reports</i> , 2000, 2, 402-410.	4.7	42
233	The Role of the Thymus in Immune Reconstitution in Aging, Bone Marrow Transplantation, and HIV-1 Infection. <i>Annual Review of Immunology</i> , 2000, 18, 529-560.	21.8	430
234	Changes in thymic function with age and during the treatment of HIV infection. <i>Nature</i> , 1998, 396, 690-695.	27.8	1,778

#	ARTICLE	IF	CITATIONS
235	The human thymus. Immunologic Research, 1998, 18, 61-78.	2.9	62
236	The human thymus. Immunologic Research, 1998, 18, 175-192.	2.9	64
237	Normalization of the peripheral blood T cell receptor V beta repertoire after cultured postnatal human thymic transplantation in DiGeorge syndrome. Journal of Clinical Immunology, 1997, 17, 167-175.	3.8	26
238	Conformational Preferences of a Chimeric Peptide HIV-1 Immunogen from the C4~V3 Domains of gp120 Envelope Protein of HIV-1 CANOA Based on Solution NMR:~ Comparison to a Related Immunogenic Peptide from HIV-1 RF. Biochemistry, 1996, 35, 5158-5165.	2.5	34
239	The mouse CD7 gene: identification of a new element common to the human CD7 and mouse Thy-1 promoters. Immunogenetics, 1996, 44, 108-114.	2.4	1
240	The mouseCD7 gene: Identification of a new element common to the humanCD7 and mouseThy-1 promoters. Immunogenetics, 1996, 44, 108-114.	2.4	6
241	Response : HIV Viral Load Assay. Science, 1996, 271, 1043-1043.	12.6	0
242	<i>Response</i> : HIV Viral Load Assay. Science, 1996, 271, 1043-1043.	12.6	1
243	<i>Response</i> : HIV Quasispecies and Resampling. Science, 1996, 273, 416-416.	12.6	0
244	Distribution of CD44 variant isoforms in human skin: differential expression in components of benign and malignant epithelia. Journal of Cutaneous Pathology, 1995, 22, 536-545.	1.3	18
245	Increase in TCR?? T lymphocytes in synovia from rheumatoid arthritis patients with active synovitis. Journal of Clinical Immunology, 1992, 12, 130-138.	3.8	33
246	In vivo models of human lymphopoiesis and autoimmunity in severe combined immune deficient mice. Journal of Clinical Immunology, 1992, 12, 311-324.	3.8	18
247	Measurement of an adhesion molecule as an indicator of inflammatory disease activity: Up~regulation of the receptor for hyaluronate (CD44) in rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 1434-1443.	6.7	168
248	Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis and Rheumatism, 1989, 32, 22-30.	6.7	186
249	Synovial microenvironment-t cell interactions. Arthritis and Rheumatism, 1988, 31, 947-955.	6.7	57
250	Ontogeny of the human thymus during fetal development. Journal of Clinical Immunology, 1987, 7, 81-97.	3.8	141
251	Human Erythrocyte Antigens. Vox Sanguinis, 1987, 52, 236-243.	1.5	50
252	Rheumatoid arthritis and sterile corneal ulceration. Arthritis and Rheumatism, 1984, 27, 606-614.	6.7	18

#	ARTICLE	IF	CITATIONS
253	Leukemia-associated arthritis: identification of leukemic cells in synovial fluid using monoclonal and polyclonal antibodies. <i>Arthritis and Rheumatism</i> , 1984, 27, 1306-1308.	6.7	34
254	Analysis of Fc γ 3 receptors on human peripheral blood leukocytes by flow microfluorometry. I. Receptor distributions on monocytes, T γ 3 cells and cells labeled with the 3A1 anti-T cell monoclonal antibody. <i>European Journal of Immunology</i> , 1982, 12, 474-479.	2.9	23
255	Human T Lymphocyte Antigens as Defined by Monoclonal Antibodies. <i>Immunological Reviews</i> , 1981, 57, 127-161.	6.0	208
256	AAAARapid Selection of HIV Envelopes that Bind to Neutralizing Antibody B Cell Lineage Members with Functional Improbable Mutations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1